Elotuzumab for the treatment of multiple myeloma

被引：0
作者：
Yucai Wang
Larysa Sanchez
David S. Siegel
Michael L. Wang
机构：
[1] Rutgers New Jersey Medical School,Department of Medicine
[2] Hackensack University Medical Center,Division of Multiple Myeloma, John Theurer Cancer Center
[3] The University of Texas M. D. Anderson Cancer Center,Department of Lymphoma/Myeloma, Division of Cancer Medicine
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
Natural Killer Cell; Multiple Myeloma; Thalidomide; Bortezomib; Maximum Tolerate Dose;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer (NK) cells. Elotuzumab demonstrated significant anti-myeloma activity in preclinical studies, and its mechanisms of action include mediating antibody-dependent cell-mediated cytotoxicity, enhancing cytotoxicity of NK cells, and inhibiting MM cell interaction with bone marrow stromal cells. In clinical trials, elotuzumab in combination with immunomodulatory drugs and proteasome inhibitors has demonstrated an excellent efficacy and safety profile in treating MM.
引用
收藏
相关论文
共 309 条
[1]  
Singhal S(1999)Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1565-1571
[2]  
Mehta J(2002)Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma Blood 100 3063-3067
[3]  
Desikan R(2003)A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2609-2617
[4]  
Ayers D(2014)Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients Leukemia 28 1122-1128
[5]  
Roberson P(2012)Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study Leukemia 26 149-157
[6]  
Eddlemon P(2015)Emerging therapies in multiple myeloma Am J Clin Oncol 38 315-321
[7]  
Munshi N(2008)CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma Clin Cancer Res 14 2775-2784
[8]  
Anaissie E(2013)CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma Crit Rev Oncol Hematol 88 168-177
[9]  
Wilson C(2014)Profile of elotuzumab and its potential in the treatment of multiple myeloma Blood Lymphat Cancer 2014 15-27
[10]  
Dhodapkar M(2001)Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family J Immunol 167 5517-5521
12345678910